{"id":43579,"date":"2026-09-02T14:57:07","date_gmt":"2026-09-02T14:57:07","guid":{"rendered":"https:\/\/eurekainfomed.it\/en\/?p=43579"},"modified":"2026-09-02T14:57:07","modified_gmt":"2026-09-02T14:57:07","slug":"regulatory-affairs-maintaining-control-throughout-the-product-lifecycle","status":"publish","type":"post","link":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/","title":{"rendered":"Regulatory Affairs: maintaining control throughout the product lifecycle"},"content":{"rendered":"

An incomplete dossier, a variation submitted too late, or a claim that is not fully aligned with technical documentation can delay market access and create consequences that extend beyond a single regulatory activity. In Regulatory Affairs<\/strong>, process quality depends on the ability to keep data, documents, responsibilities, and timelines aligned throughout the entire product lifecycle.<\/p>\n

\n

For pharmaceutical, biotech, biomedical, and medtech companies, Regulatory Affairs is not simply the function responsible for preparing a submission. It serves as a bridge between development, quality, clinical, medical affairs, pharmacovigilance, manufacturing, and commercial teams, translating regulatory requirements into documented and verifiable actions. When this coordination is missing, even accurate information can be used at the wrong time, in the wrong version, or in the wrong context.<\/p>\n

Regulatory Affairs: A Function of Continuity<\/h2>\n

The objective of Regulatory Affairs is to demonstrate, through appropriate evidence and in a format acceptable to the relevant competent authority or notified body, that a product complies with applicable requirements. For medicinal products, this means supporting quality, safety, and efficacy through dossiers, marketing authorizations, renewals, variations, and post-authorization activities. For medical devices and in vitro diagnostic devices, it involves managing technical documentation, clinical evaluation or performance evaluation, classification, labeling, post-market surveillance, and interactions with regulatory stakeholders.<\/p>\n

The difference between administrative management and effective regulatory management lies in continuity. Regulatory oversight does not end once a product reaches the market. New clinical data, manufacturing changes, safety updates, supplier modifications, claim revisions, or regulatory developments may require timely assessment. Every change must be evaluated not only for its technical content but also for its impact on regulatory status, controlled documentation, and external communications.<\/p>\n

This perspective requires clear governance: who identifies the change, who evaluates its impact, who approves the strategy, which documents must be updated, and what evidence demonstrates that the process has been followed. Clarity is not a formality. It is what makes a decision defensible during an audit, inspection, or regulatory inquiry.<\/p>\n

From Regulatory Requirement to Operational Plan<\/h2>\n

A regulatory requirement, considered in isolation, does not automatically create compliance. It must be translated into a workflow that is compatible with the product, target market, and organization responsible for managing it. Standardized solutions can be efficient for repetitive activities, but they become fragile when they fail to consider dossier maturity, supplier structures, or the distribution of responsibilities between local affiliates and global headquarters.<\/p>\n

An effective regulatory plan begins with an assessment of the current situation. Which authorizations or certifications are in place? Which documents are available, approved, and mutually consistent? Which deadlines are approaching? Are there open change controls that may affect labeling, product information, CMC dossiers, technical documentation, or clinical data?<\/p>\n

The answers to these questions help establish realistic priorities, reducing both the risk of delays and the inefficient use of internal resources.<\/p>\n

Strategy Depends on the Product and the Market<\/h2>\n

There is no single regulatory pathway that applies to every technology or medicinal product. Regulatory strategy depends on factors such as classification, intended use, risk profile, availability of evidence, existence of comparable products, and target countries.<\/p>\n

For a biotech startup, the priority may be building a regulatory roadmap that ensures development data remain organized and reusable. For an established pharmaceutical company, the focus may be managing a high volume of variations, maintaining post-marketing compliance, or implementing local activities resulting from European regulatory decisions. For a medtech company, it may involve assessing whether technical documentation remains adequate following a new claim or a substantial product modification.<\/p>\n

In every case, anticipating regulatory questions reduces costly rework later in the process.<\/p>\n

The Dossier as a Controlled System<\/h2>\n

A dossier is not simply a collection of files. It is a controlled documentation system in which every component must have a defined origin, version, approval status, and logical connection to related documents. The quality of a single document cannot compensate for inconsistencies with instructions for use, clinical evaluations, risk management files, promotional materials, or post-market surveillance evidence.<\/p>\n

Document control therefore plays a central role. It requires naming conventions, updated registers, defined approval workflows, accessible archiving systems, and a clear distinction between drafts, effective versions, and obsolete documents.<\/p>\n

When documentation is managed by multiple functions or external partners, these elements become essential for preventing discrepancies and ensuring full traceability of decisions.<\/p>\n

Areas Requiring the Highest Level of Coordination<\/h2>\n

The complexity of Regulatory Affairs becomes most evident at the points where functions intersect. A regulatory variation may require updates to product information. A safety signal may affect educational materials. A modification to technical documentation may necessitate a reassessment of promotional claims. Managing these activities in separate silos increases the risk of delayed alignment.<\/p>\n

Particularly sensitive areas include:<\/p>\n

    \n
  • Product classification and qualification, which determine regulatory requirements, evaluation pathways, and required levels of evidence.<\/li>\n
  • Preparation and maintenance of dossiers, registrations, notifications, renewals, and variations.<\/li>\n
  • Review of labels, IFUs, SmPCs, package leaflets, and scientific materials to ensure consistency with authorization status.<\/li>\n
  • Management of clinical, bibliographic, and technical-scientific evidence supporting regulatory documentation and claims.<\/li>\n
  • Coordination with quality, pharmacovigilance, and post-market surveillance functions to ensure relevant information is assessed and managed within appropriate timelines.<\/li>\n<\/ul>\n

    Not all activities need to be managed internally. An outsourcing model can provide flexibility, particularly when specialized expertise is required for a specific project phase, a remediation initiative, a submission, or a temporary increase in workload. The key is defining operational boundaries, decision-making responsibilities, escalation pathways, and knowledge-transfer methods. Delegating execution does not mean transferring corporate responsibility.<\/p>\n

    Regulatory Compliance and Scientific Quality<\/h2>\n

    In life sciences, compliance involves more than maintaining the required documentation. It also depends on the quality of available evidence, the correct interpretation of data, and the consistency between what is claimed, what is supported, and what is authorized.<\/p>\n

    A literature search conducted using explicit and reproducible criteria, for example, may support a clinical evaluation, a scientific rationale, or a regulatory response. Without a verifiable methodology, the value of the evidence becomes more difficult to defend.<\/p>\n

    The same principle applies to medical writing and specialized translations. A text may be linguistically accurate yet remain unsuitable if it changes the clinical meaning, introduces ambiguity, or fails to respect approved terminology. Regulatory review should therefore work in close collaboration with scientific and linguistic experts rather than intervene only at the end of the process.<\/p>\n

    This is why an integrated partner can be particularly valuable when a project requires multiple coordinated areas of expertise. Eureka InfoMed acts as an extension of internal teams by combining regulatory, scientific, quality, and pharmacovigilance competencies to maintain document and process consistency during critical phases.<\/p>\n

    Measuring the Strength of the Regulatory Process<\/h2>\n

    The performance of a regulatory function cannot be measured solely by submission deadlines. Additional indicators include first-pass submission completeness, the number of requests for additional information, variation management timelines, the update status of controlled documents, and the time required to assess change controls.<\/p>\n

    These metrics should not become a bureaucratic exercise. Their purpose is to identify where information is being lost, where approvals are delayed, and where responsibilities are unclear. Periodic reviews of process weaknesses make it possible to update procedures, responsibility matrices, and training plans before a nonconformity develops into an external issue.<\/p>\n

    Regulations evolve, just as products, evidence, and organizations do. The most reliable response is not to react to every new requirement with isolated actions but to build a regulatory function capable of understanding change, evaluating its impact, and documenting consistent decisions. It is through this daily discipline that confidence in a well-managed regulatory pathway is achieved.<\/p>\n

    Sources<\/h2>\n
      \n
    1. International Council for Harmonisation (ICH). ICH Q10 Pharmaceutical Quality System<\/em>.<\/li>\n
    2. International Council for Harmonisation (ICH). ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management<\/em>.<\/li>\n
    3. European Parliament and Council of the European Union. Regulation (EU) 2017\/745 on Medical Devices (MDR)<\/em>.<\/li>\n
    4. European Medicines Agency (EMA). Regulatory Science Strategy to 2025<\/em>.<\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

      An incomplete dossier, a variation submitted too late, or a claim that is not fully aligned with technical documentation can delay market access and create consequences that extend beyond a…<\/p>\n","protected":false},"author":16,"featured_media":43580,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-43579","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news"],"yoast_head":"\nRegulatory Affairs: maintaining control throughout the product lifecycle - Eureka Info Med<\/title>\n<meta name=\"description\" content=\"Learn how Regulatory Affairs supports compliance throughout the product lifecycle, from submissions and regulatory strategy to document control, change management, and market access.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regulatory Affairs: maintaining control throughout the product lifecycle - Eureka Info Med\" \/>\n<meta property=\"og:description\" content=\"Learn how Regulatory Affairs supports compliance throughout the product lifecycle, from submissions and regulatory strategy to document control, change management, and market access.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/\" \/>\n<meta property=\"og:site_name\" content=\"Eureka Info Med\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T14:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/eurekainfomed.it\/en\/wp-content\/uploads\/2026\/09\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"EleonoraHay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"EleonoraHay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/\"},\"author\":{\"name\":\"EleonoraHay\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/#\\\/schema\\\/person\\\/a7fea1f3cb636f2ae5986e9a8e805f55\"},\"headline\":\"Regulatory Affairs: maintaining control throughout the product lifecycle\",\"datePublished\":\"2026-09-02T14:57:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/\"},\"wordCount\":1295,\"image\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/\",\"url\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/\",\"name\":\"Regulatory Affairs: maintaining control throughout the product lifecycle - Eureka Info Med\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp\",\"datePublished\":\"2026-09-02T14:57:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/#\\\/schema\\\/person\\\/a7fea1f3cb636f2ae5986e9a8e805f55\"},\"description\":\"Learn how Regulatory Affairs supports compliance throughout the product lifecycle, from submissions and regulatory strategy to document control, change management, and market access.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#primaryimage\",\"url\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp\",\"contentUrl\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regulatory Affairs: maintaining control throughout the product lifecycle\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/\",\"name\":\"Eureka Info Med\",\"description\":\"documentazione medico-scientifica e farmacovigilanza\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/#\\\/schema\\\/person\\\/a7fea1f3cb636f2ae5986e9a8e805f55\",\"name\":\"EleonoraHay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d69f2b5701b09e9eb5e59e8f2826c37ad6c9c89c09b3542f5773a6e61157663?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d69f2b5701b09e9eb5e59e8f2826c37ad6c9c89c09b3542f5773a6e61157663?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d69f2b5701b09e9eb5e59e8f2826c37ad6c9c89c09b3542f5773a6e61157663?s=96&d=mm&r=g\",\"caption\":\"EleonoraHay\"},\"url\":\"https:\\\/\\\/eurekainfomed.it\\\/en\\\/author\\\/eleonorahay\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regulatory Affairs: maintaining control throughout the product lifecycle - Eureka Info Med","description":"Learn how Regulatory Affairs supports compliance throughout the product lifecycle, from submissions and regulatory strategy to document control, change management, and market access.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/","og_locale":"en_US","og_type":"article","og_title":"Regulatory Affairs: maintaining control throughout the product lifecycle - Eureka Info Med","og_description":"Learn how Regulatory Affairs supports compliance throughout the product lifecycle, from submissions and regulatory strategy to document control, change management, and market access.","og_url":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/","og_site_name":"Eureka Info Med","article_published_time":"2026-09-02T14:57:07+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/eurekainfomed.it\/en\/wp-content\/uploads\/2026\/09\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp","type":"image\/webp"}],"author":"EleonoraHay","twitter_card":"summary_large_image","twitter_misc":{"Written by":"EleonoraHay","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#article","isPartOf":{"@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/"},"author":{"name":"EleonoraHay","@id":"https:\/\/eurekainfomed.it\/en\/#\/schema\/person\/a7fea1f3cb636f2ae5986e9a8e805f55"},"headline":"Regulatory Affairs: maintaining control throughout the product lifecycle","datePublished":"2026-09-02T14:57:07+00:00","mainEntityOfPage":{"@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/"},"wordCount":1295,"image":{"@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#primaryimage"},"thumbnailUrl":"https:\/\/eurekainfomed.it\/en\/wp-content\/uploads\/2026\/09\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/","url":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/","name":"Regulatory Affairs: maintaining control throughout the product lifecycle - Eureka Info Med","isPartOf":{"@id":"https:\/\/eurekainfomed.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#primaryimage"},"image":{"@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#primaryimage"},"thumbnailUrl":"https:\/\/eurekainfomed.it\/en\/wp-content\/uploads\/2026\/09\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp","datePublished":"2026-09-02T14:57:07+00:00","author":{"@id":"https:\/\/eurekainfomed.it\/en\/#\/schema\/person\/a7fea1f3cb636f2ae5986e9a8e805f55"},"description":"Learn how Regulatory Affairs supports compliance throughout the product lifecycle, from submissions and regulatory strategy to document control, change management, and market access.","breadcrumb":{"@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#primaryimage","url":"https:\/\/eurekainfomed.it\/en\/wp-content\/uploads\/2026\/09\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp","contentUrl":"https:\/\/eurekainfomed.it\/en\/wp-content\/uploads\/2026\/09\/affari-regolatori-controllo-lungo-il-ciclo-di-vita-featured.webp","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/eurekainfomed.it\/en\/regulatory-affairs-maintaining-control-throughout-the-product-lifecycle\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurekainfomed.it\/en\/"},{"@type":"ListItem","position":2,"name":"Regulatory Affairs: maintaining control throughout the product lifecycle"}]},{"@type":"WebSite","@id":"https:\/\/eurekainfomed.it\/en\/#website","url":"https:\/\/eurekainfomed.it\/en\/","name":"Eureka Info Med","description":"documentazione medico-scientifica e farmacovigilanza","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurekainfomed.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurekainfomed.it\/en\/#\/schema\/person\/a7fea1f3cb636f2ae5986e9a8e805f55","name":"EleonoraHay","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4d69f2b5701b09e9eb5e59e8f2826c37ad6c9c89c09b3542f5773a6e61157663?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4d69f2b5701b09e9eb5e59e8f2826c37ad6c9c89c09b3542f5773a6e61157663?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4d69f2b5701b09e9eb5e59e8f2826c37ad6c9c89c09b3542f5773a6e61157663?s=96&d=mm&r=g","caption":"EleonoraHay"},"url":"https:\/\/eurekainfomed.it\/en\/author\/eleonorahay\/"}]}},"_links":{"self":[{"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/posts\/43579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/comments?post=43579"}],"version-history":[{"count":1,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/posts\/43579\/revisions"}],"predecessor-version":[{"id":43581,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/posts\/43579\/revisions\/43581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/media\/43580"}],"wp:attachment":[{"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/media?parent=43579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/categories?post=43579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurekainfomed.it\/en\/wp-json\/wp\/v2\/tags?post=43579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}